Clinical Trials Logo

Non-Small Cell Lung Cancer clinical trials

View clinical trials related to Non-Small Cell Lung Cancer.

Filter by:

NCT ID: NCT06452433 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

This study evaluated the efficacy and safety of gumarontinib combined with third-generation EGFR-TKI in the treatment of locally advanced or metastatic NSCLC with MET amplification after first-line EGFR-TKI failure, without limiting the type of third-generation EGFR-TKI. The study was divided into 2 cohorts: Cohort 1 included patients with MET amplification after third-generation EGFR-TKI first-line therapy resistance, and cohort 2 included patients with MET amplification after first-generation EGFR-TKI first-line therapy resistance.

NCT ID: NCT06451497 Recruiting - Prostate Cancer Clinical Trials

Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Start date: May 22, 2024
Phase: Phase 1
Study type: Interventional

This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Pembrolizumab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.

NCT ID: NCT06448754 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Volrustomig Priming Regimens Exploratory Phase II Platform Study

eVOLVE-01
Start date: June 28, 2024
Phase: Phase 2
Study type: Interventional

Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.

NCT ID: NCT06448572 Not yet recruiting - Clinical trials for Non-Small Cell Lung Cancer

EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.

EXLIBRIS
Start date: September 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

As treatment options are limited following progression on anti PD-(L)1 and platinum-based chemotherapy, we propose this trial for patients who have failed to respond or have shown intolerance to standard therapies or for whom no appropriate therapies are known to provide clinical benefit. Considering the strong therapeutic rationale of an association between antineoplastic immunotherapy and EXL01 (single-strain of F. prausnitzii, a bacteria which is a dominant member of the healthy gut microbiota), we propose to assess this combination for NSCLC treatment. This is a pilot, Phase I/II, one-arm, monocentric study evaluating the combination of EXL01 with nivolumab treatment for Non-Small Cell Lung Cancer patients.

NCT ID: NCT06448364 Recruiting - Colorectal Cancer Clinical Trials

A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination

LTbR
Start date: May 9, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to learn about the safety (the impact of the study drug on the participant's body), effects of the study drug alone or in combination with bevacizumab or sasanlimab, and to find the best dose. This study is seeking participants who have solid tumors that: - have advanced (cancer that doesn't disappear or stay away with treatment) or - has spread to other parts of the body (metastatic). This includes (but limited to) the following cancer types: - Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body. - Colorectal Cancer (CRC): This is a disease where cells in the colon or rectum grow out of control. - Urothelial Cancer (UC): This is a cancer that starts in the urinary systems. - Melanoma: Skin cancer that develops when melanocytes (the cells that give the skin its tan or brown color) start to grow out of control. All participants in this study will receive the study medication (PF-07329640) as an IV infusion (given directly into a vein) at the study clinic every week for repeating 28-day cycles. Depending on which part of the study participants are enrolled in they will receive the study medication (PF-07329640 alone or in combination with other anti-cancer medications (bevacizumab or sasanlimab). Bevacizumab is given in the clinic as IV infusion every two weeks and sasanlimab is given as a shot under the skin every 4 weeks. Participants can continue to take the study medication (PF-07329640) and bevacizumab until their cancer is no longer responding. Participants who are taking sasanlimab may receive it for up to 2 years. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and effective. Participants will be involved in this study for up to 4 years. During this time, they will have a study visit every week. After they have stopped taking the study medication (at about at 2 years) they will be followed for another two years to see how they are doing.

NCT ID: NCT06448312 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Start date: June 2024
Phase: Phase 3
Study type: Interventional

The aim of the study is to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab as firstline treatment for patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

NCT ID: NCT06445881 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment

MSJZT-NSCLC
Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

Chemotherapy combined with immunotherapy is the current standard perioperative treatment for non-small cell lung cancer (NSCLC). However, this regimen has multiple side effects and shows variable efficacy among individuals. In China, adjunctive traditional Chinese medicine is widely accepted by lung cancer patients. Modified Si Jun Zi Tang, a classic formula in traditional Chinese medicine, is known for its benefits in unifying and strengthening the spleen. This study aims to evaluate whether the addition of Modified Si Jun Zi Tang to chemotherapy and immunotherapy during the neoadjuvant phase can improve the R0 resection rate, objective response rate (ORR), and safety in patients with resectable and potentially resectable NSCLC. Secondary objectives include assessing whether this combination can improve 1-year and 2-year disease-free survival (DFS) post-surgery. Additionally, we will collect relevant biological samples to identify tumor markers associated with efficacy, prognosis, and side effects, providing a theoretical basis for modernizing and standardizing traditional Chinese medicine.

NCT ID: NCT06444815 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of VET3-TGI in Patients With Solid Tumors

STEALTH-001
Start date: August 1, 2024
Phase: Phase 1
Study type: Interventional

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with pembrolizumab in patients with solid tumors (STEALTH-001).

NCT ID: NCT06443684 Recruiting - Clinical trials for Non Small Cell Lung Cancer

A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC

Start date: May 8, 2023
Phase:
Study type: Observational

The goal of this prospective, observational study is to explore the value of dynamic monitoring of minimal residual lesions in driver mutated stage III NSCLC for disease recurrence and prognosis assessment. The main question it aims to answer is: 1) Whether MRD(Minimal residual disease) status can predict recurrence events in stage III driven-mutant NSCLC in advance

NCT ID: NCT06440954 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases

EPIC
Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

This is a prospective interventional study clinical study to investigate the efficacy and resistance mechanisms of intrathecal pemetrexed in patients with driver gene mutations advanced NSCLC with leptomeningeal metastases.